LONDON, July 16 (Reuters) - Sanofi-Aventis SA’s (SASY.PA: Quote, Profile, Research) obesity pill Acomplia faces a tough review from European drug safety experts this week, with data suggesting officials see issues over the drug’s link with suicidal thoughts.
